Insight

Yüksel Ürün: Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers

Yüksel Ürün/X

Apr 8, 2025, 03:09

Yüksel Ürün: Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers

Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared a post on X:

“TIL therapy + pembrolizumab (SEL-TIL + P) shows 23.5% response in mismatch repair–proficient GI cancers – where immunotherapy usually fails.

Neoantigen recognition may be the key.”

“Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial”

Authors:Frank J. Lowery et al.

Yüksel Ürün

Aaron J. Dinerman Aarushi Bhasin Abraham A. Hakim Alakesh Bera Alexandra M. Gustafson Billel Gasmi cancer Chuong D. Hoang Courtney D. Seavey Frank J. Lowery Hyunmi K. Halas Ian S. Goldlust James C. Yang Jared J. Gartner Jonathan M. Hernandez Juliette G. Rault-Wang Kyle J. Hitscherich Lior Levy Lisa M. Kenney Lori S. McIntyre Maria R. Parkhurst Mei Li M. Kwong Michelle M. Langhan Nicholas D. Klemen Nivedita M. Ratnam OncoDaily Oncology Paul F. Robbins Satyajit Ray Sivasish Sindiri Sri Krishna Stephanie L. Goff Steven A. Rosenberg Thomas E. Shelton Todd D. Prickett Victoria Dulemba Yüksel Ürün

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers